Reunion Neuroscience

Reunion Neuroscience is a venture-backed, clinical-stage biotech company pioneering next-generation psychedelic-based mental health therapies. Its lead candidate, luvesilocin (RE104), a short-duration prodrug of a psilocybin-like compound, has received FDA Breakthrough Therapy Designation for postpartum depression following positive Phase 2 results. The company is targeting significant unmet needs in psychiatry with a pipeline focused on rapid-onset, durable antidepressant effects, leveraging a team with deep neuroscience drug development expertise.

Patented serotonergic psychedelic prodrug platform focused on developing short-duration, optimized compounds (e.g., luvesilocin, a prodrug of 4-OH-DiPT) that target the 5-HT2A receptor for rapid and durable antidepressant effects.

Reunion operates in a competitive psychedelics sector with players like Compass Pathways (COMP360 for TRD), Cybin (CYB003 for MDD), and MindMed developing various compounds. Reunion's differentiation is its focus on a specific short-duration prodrug (RE104) and initial targeting of postpartum depression, a distinct indication with high unmet need. However, many competitors are also pursuing next-generation, optimized psychedelic molecules.